Jefferies Group LLC reissued their buy rating on shares of Oxford BioMedica plc (LON:OXB) in a research note released on Friday. Jefferies Group LLC currently has a GBX 8 ($0.10) price target on the biopharmaceutical company’s stock.
Separately, N+1 Singer reiterated a hold rating and issued a GBX 3.30 ($0.04) target price on shares of Oxford BioMedica plc in a research note on Tuesday, November 29th.
Oxford BioMedica plc (LON:OXB) traded down 0.36% during midday trading on Friday, reaching GBX 5.50. The company’s stock had a trading volume of 6,338,186 shares. Oxford BioMedica plc has a 1-year low of GBX 2.98 and a 1-year high of GBX 6.86. The company’s market capitalization is GBX 146.57 million. The company has a 50 day moving average of GBX 4.38 and a 200-day moving average of GBX 3.89.
Your IP Address:
In other news, insider Lorenzo Tallarigo purchased 67,165 shares of the stock in a transaction on Friday, February 24th. The stock was purchased at an average price of GBX 4 ($0.05) per share, with a total value of £2,686.60 ($3,318.02).
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.